DN1679 

DN1679 is a potent, selective and orally active CRBN-dependent CDK12/13 PROTAC dual degrader. DN1679 shows DC₅₀ of 8.8/9.8 nM (MDA-MB-231), 5.1/6.4 nM (MDA-MB-157) and 17.2/15.8 nM (MDA-MB-468) for CDK12/13. DN1679 can downregulate DNA damage response gene mRNA levels, such as ATM, ATR, BRCA1 and RAD51. DN1679 demonstrates a potent synergistic anti-tumor effect companied with Olaparib (HY-10162). DN1679 can be used for research of triple-negative breast cance^[1]. (Pink: CDK12 and CDK13 ligand (HY-181036); Blue: Cereblon ligand (HY-W093272); Black: linker).

DN1679 inhibits MDA-MB-231, MDA-MB-157 and MDA-MB-468 cells proliferation with IC₅₀ values of 31.7, 49.1 and 121.4 nM. DN1679 has low cytotoxicity to normal human cell lines (MCF10A and NCM460) (IC₅₀ of 236.9 and 378.5 nM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1068.10

C₅₂H₅₃F₄N₁₁O₈S

CC(N([C@@H]1CC[C@H](CC1)NC2=NC(C3=CN=CC(S(C)(=O)=O)=C3)=C(C=N2)C(F)(F)F)C4=CC=C(C=C4)C5=CN=C(N=C5)O[C@H]6CN(CC6)CC7CCN(CC7)C8=CC(C(N9C%10CCC(NC%10=O)=O)=O)=C(C=C8F)C9=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chen D, et al. Discovery of DN1679 as a Potent, Orally Bioavailable, and Highly Selective CDK12/13 Dual Degrader for the Treatment of Triple-Negative Breast Cancer. J Med Chem. 2026 Jan 22;69(2):1033-1048.  [Content Brief]